List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2587457/publications.pdf Version: 2024-02-01



ΖΙΥΛΙΙΟ ΡΛΗΜΑΝ

#	Article	IF	CITATIONS
1	Curcumin: A natural antiinflammatory agent. Indian Journal of Pharmacology, 2005, 37, 141.	0.7	176
2	Non-destructive methods of characterization of risperidone solid lipid nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 127-137.	4.3	149
3	Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett–Burman design. International Journal of Pharmaceutics, 2010, 389, 186-194.	5.2	138
4	Nanomedicines as Cancer Therapeutics: Current Status. Current Cancer Drug Targets, 2013, 13, 362-378.	1.6	123
5	3D printing for drug delivery and biomedical applications. Drug Discovery Today, 2020, 25, 1668-1681.	6.4	119
6	Selective laser sintering 3D printing – an overview of the technology and pharmaceutical applications. Drug Development and Industrial Pharmacy, 2020, 46, 869-877.	2.0	116
7	Quality by design approach for formulation development: A case study of dispersible tablets. International Journal of Pharmaceutics, 2012, 423, 167-178.	5.2	110
8	Physico-mechanical and Stability Evaluation of Carbamazepine Cocrystal with Nicotinamide. AAPS PharmSciTech, 2011, 12, 693-704.	3.3	107
9	Additive Manufacturing with 3D Printing: Progress from Bench to Bedside. AAPS Journal, 2018, 20, 101.	4.4	90
10	Crystallinity evaluation of tacrolimus solid dispersions by chemometric analysis. International Journal of Pharmaceutics, 2012, 423, 341-350.	5.2	89
11	Electroporation: An Avenue for Transdermal Drug Delivery. Current Drug Delivery, 2010, 7, 125-136.	1.6	85
12	Nanometric gold in cancer nanotechnology: current status and future prospect. Journal of Pharmacy and Pharmacology, 2013, 65, 634-651.	2.4	76
13	Characterization of 5-fluorouracil microspheres for colonic delivery. AAPS PharmSciTech, 2006, 7, E113-E121.	3.3	75
14	Understanding the effects of formulation and process variables on the printlets quality manufactured by selective laser sintering 3D printing. International Journal of Pharmaceutics, 2019, 570, 118651.	5.2	72
15	Removal of peroxides in polyethylene glycols by vacuum drying: Implications in the stability of biotech and pharmaceutical formulations. AAPS PharmSciTech, 2006, 7, E47.	3.3	68
16	Risperidone solid dispersion for orally disintegrating tablet: Its formulation design and non-destructive methods of evaluation. International Journal of Pharmaceutics, 2010, 400, 49-58.	5.2	65
17	Development of performance matrix for generic product equivalence of acyclovir topical creams. International Journal of Pharmaceutics, 2014, 475, 110-122.	5.2	64
18	Solid Matrix Based Lipidic Nanoparticles in Oral Cancer Chemotherapy: Applications and Pharmacokinetics. Current Drug Metabolism, 2015, 16, 633-644.	1.2	59

#	Article	IF	CITATIONS
19	Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments. International Journal of Pharmaceutics, 2015, 493, 412-425.	5.2	54
20	3D-printing of lopinavir printlets by selective laser sintering and quantification of crystalline fraction by XRPD-chemometric models. International Journal of Pharmaceutics, 2021, 592, 120059.	5.2	50
21	Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil. Colloids and Surfaces B: Biointerfaces, 2008, 65, 300-307.	5.0	47
22	Product and process understanding of a novel pediatric anti-HIV tenofovir niosomes with a high-pressure homogenizer. European Journal of Pharmaceutical Sciences, 2011, 44, 93-102.	4.0	44
23	Formulation Optimization of Selective Laser Sintering 3D-Printed Tablets of Clindamycin Palmitate Hydrochloride by Response Surface Methodology. AAPS PharmSciTech, 2020, 21, 232.	3.3	44
24	Assessing impact of formulation and process variables on in-vitro performance of directly compressed abuse deterrent formulations. International Journal of Pharmaceutics, 2016, 502, 138-150.	5.2	41
25	Lipid-Based Nanosystem As Intelligent Carriers for Versatile Drug Delivery Applications. Current Pharmaceutical Design, 2020, 26, 1167-1180.	1.9	41
26	Quality by Design Approach for Understanding the Critical Quality Attributes of Cyclosporine Ophthalmic Emulsion. Molecular Pharmaceutics, 2014, 11, 787-799.	4.6	40
27	Evaluation of Anticancer Drug-Loaded Nanoparticle Characteristics by Nondestructive Methodologies. AAPS PharmSciTech, 2012, 13, 611-622.	3.3	37
28	Development of meloxicam <i>in situ</i> implant formulation by quality by design principle. Drug Development and Industrial Pharmacy, 2014, 40, 66-73.	2.0	37
29	Kinetics of drug release from ointments: Role of transient-boundary layer. International Journal of Pharmaceutics, 2015, 494, 31-39.	5.2	37
30	Improvement of Physicochemical Properties of an Antiepileptic Drug by Salt Engineering. AAPS PharmSciTech, 2012, 13, 793-801.	3.3	35
31	Omega – 3 Fatty Acids as Pharmacotherapeutics in Psoriasis: Current Status and Scope of Nanomedicine in its Effective Delivery. Current Drug Targets, 2013, 14, 708-722.	2.1	34
32	Chemometric Model Development and Comparison of Raman and 13C Solid-State Nuclear Magnetic Resonance–Chemometric Methods for Quantification of Crystalline/Amorphous Warfarin Sodium Fraction in the Formulations. Journal of Pharmaceutical Sciences, 2015, 104, 2550-2558.	3.3	33
33	Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment. International Journal of Pharmaceutics, 2015, 495, 783-791.	5.2	33
34	Online Monitoring of PLGA Microparticles Formation Using Lasentec Focused Beam Reflectance (FBRM) and Particle Video Microscope (PVM). AAPS Journal, 2010, 12, 254-262.	4.4	31
35	In-vivo evaluation in rats of colon-specific microspheres containing 5-fluorouracil. Journal of Pharmacy and Pharmacology, 2010, 60, 615-623.	2.4	30
36	Orally disintegrating tablet of novel salt of antiepileptic drug: Formulation strategy and evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 1300-1309.	4.3	30

#	Article	IF	CITATIONS
37	Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin. Pharmaceutical Development and Technology, 2012, 17, 457-465.	2.4	29
38	Effects of excipients and curing process on the abuse deterrent properties of directly compressed tablets. International Journal of Pharmaceutics, 2017, 517, 303-311.	5.2	28
39	Chemometric Methods for the Quantification of Crystalline Tacrolimus in Solid Dispersion by Powder Xâ€Ray Diffractrometry. Journal of Pharmaceutical Sciences, 2014, 103, 2819-2828.	3.3	27
40	Effect of Isopropyl Myristate on Transdermal Permeation of Testosterone From Carbopol Gel. Journal of Pharmaceutical Sciences, 2017, 106, 1805-1813.	3.3	25
41	Tannate complexes of antihistaminic drug: Sustained release and taste masking approaches. International Journal of Pharmaceutics, 2012, 422, 91-100.	5.2	24
42	Assessing the impact of nimodipine devitrification in the ternary cosolvent system through quality by design approach. International Journal of Pharmaceutics, 2013, 455, 113-123.	5.2	23
43	Chemometric Evaluation of Near Infrared, Fourier Transform Infrared, and Raman Spectroscopic Models for the Prediction of Nimodipine Polymorphs. Journal of Pharmaceutical Sciences, 2013, 102, 4024-4035.	3.3	23
44	Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities. AAPS PharmSciTech, 2019, 20, 166.	3.3	23
45	Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer's Disease. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1315-1324.	1.4	23
46	Comparison of X-ray Powder Diffraction and Solid-State Nuclear Magnetic Resonance in Estimating Crystalline Fraction of Tacrolimus in Sustained-Release Amorphous Solid Dispersion and Development of Discriminating Dissolution Method. Journal of Pharmaceutical Sciences, 2015, 104, 1777-1786.	3.3	22
47	Formulation and Evaluation of a Protein-loaded Solid Dispersions by Non-destructive Methods. AAPS Journal, 2010, 12, 158-170.	4.4	21
48	Cholorpheniramine tannate complexes: Physicochemical, chemometric, and taste masking evaluation. International Journal of Pharmaceutics, 2012, 436, 582-592.	5.2	21
49	Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product. International Journal of Pharmaceutics, 2015, 495, 19-30.	5.2	21
50	Effect of processing parameters and controlled environment storage on the disproportionation and dissolution of extended-release capsule of phenytoin sodium. International Journal of Pharmaceutics, 2018, 550, 290-299.	5.2	21
51	Ocular pharmacoscintigraphic and aqueous humoral drug availability of ganciclovir-loaded mucoadhesive nanoparticles in rabbits. European Journal of Nanomedicine, 2013, 5, .	0.6	20
52	Quantitative estimation of phenytoin sodium disproportionation in the formulations using vibration spectroscopies and multivariate methodologies. International Journal of Pharmaceutics, 2018, 539, 65-74.	5.2	20
53	Evaluation of In-Use Stability of Anticoagulant Drug Products: Warfarin Sodium. Journal of Pharmaceutical Sciences, 2015, 104, 4232-4240.	3.3	19
54	Performance of Opportunistic Receiver Beam Selection in Multiaperture OWC Systems Over Foggy Channels. IEEE Systems Journal, 2020, 14, 4036-4046.	4.6	19

#	Article	IF	CITATIONS
55	Near-Infrared and Fourier Transform Infrared Chemometric Methods for the Quantification of Crystalline Tacrolimus from Sustained-Release Amorphous Solid Dispersion. Journal of Pharmaceutical Sciences, 2014, 103, 2376-2385.	3.3	18
56	Development and validation of X-ray diffraction method for quantitative determination of crystallinity in warfarin sodium products. International Journal of Pharmaceutics, 2015, 493, 1-6.	5.2	18
57	Blend of cellulose ester and enteric polymers for delayed and enteric coating of core tablets of hydrophilic and hydrophobic drugs. International Journal of Pharmaceutics, 2019, 567, 118462.	5.2	18
58	Application of NIR chemometric methods for quantification of the crystalline fraction of warfarin sodium in drug product. Drug Development and Industrial Pharmacy, 2016, 42, 584-594.	2.0	17
59	Determination of tacrolimus crystalline fraction in the commercial immediate release amorphous solid dispersion products by a standardized X-ray powder diffraction method with chemometrics. International Journal of Pharmaceutics, 2014, 475, 462-470.	5.2	16
60	Chemometric Models for Quantification of Carbamazepine Anhydrous and Dihydrate Forms in the Formulation. Journal of Pharmaceutical Sciences, 2019, 108, 1211-1219.	3.3	16
61	Printing of personalized medication using binder jetting 3D printer. , 2020, , 473-481.		16
62	Root cause evaluation of particulates in the lyophilized indomethacin sodium trihydrate plug for parenteral administration. International Journal of Pharmaceutics, 2014, 473, 545-551.	5.2	15
63	Evaluation of Abuse-Deterrent Characteristics of Tablets Prepared via Hot-Melt Extrusion. AAPS PharmSciTech, 2019, 20, 230.	3.3	15
64	Spectroscopic-Based Chemometric Models for Quantifying Low Levels of Solid-State Transitions in Extended Release Theophylline Formulations. Journal of Pharmaceutical Sciences, 2016, 105, 97-105.	3.3	14
65	Impact of formulation and process variables on solid-state stability of theophylline in controlled release formulations. International Journal of Pharmaceutics, 2016, 499, 20-28.	5.2	13
66	Very-Rapidly Dissolving Printlets of Isoniazid Manufactured by SLS 3D Printing: In Vitro and In Vivo Characterization. Molecular Pharmaceutics, 2022, 19, 2937-2949.	4.6	13
67	Transdermal Delivery of Flurbiprofen: Permeation Enhancement, Design, Pharmacokinetic, and Pharmacodynamic Studies in Albino Rats. Pharmaceutical Development and Technology, 2005, 10, 343-351.	2.4	12
68	Spectral and Spatial Characterization of Protein Loaded PLGA Nanoparticles. Journal of Pharmaceutical Sciences, 2010, 99, 1180-1192.	3.3	12
69	Ultra-long acting prodrug of dolutegravir and delivery system – Physicochemical, pharmacokinetic and formulation characterizations. International Journal of Pharmaceutics, 2021, 607, 120889.	5.2	12
70	Ion-Pair Chromatography for Simultaneous Analysis of Ethionamide and Pyrazinamide from Their Porous Microparticles. AAPS PharmSciTech, 2013, 14, 1313-1320.	3.3	11
71	Quality and In-Use Stability Comparison of Brand and Generics of Extended-Release Phenytoin Sodium Capsules. Journal of Pharmaceutical Sciences, 2019, 108, 1808-1817.	3.3	11
72	Development of Methamphetamine Abuse–Deterrent Formulations Using Sucrose Acetate Isobutyrate. Journal of Pharmaceutical Sciences, 2020, 109, 1338-1346.	3.3	11

#	Article	IF	CITATIONS
73	Characterization of a Nonribosomal Peptide Antibiotic Solid Dispersion Formulation by Process Analytical Technologies Sensors. Journal of Pharmaceutical Sciences, 2013, 102, 4337-4346.	3.3	10
74	Simple and Sensitive High-Performance Liquid Chromatographic Method for Determination of Transdermally Applied Flurbiprofen in Rat Plasma and Excised Skin Samples. Chromatographia, 2005, 62, 493-497.	1.3	9
75	Hunter screening design to understand the product variability of solid dispersion formulation of a peptide antibiotic. International Journal of Pharmaceutics, 2013, 456, 572-582.	5.2	9
76	Leachable diphenylguanidine from rubber closures used in pre-filled syringes: A case study to understand solid and solution interactions with oxytocin. International Journal of Pharmaceutics, 2017, 532, 491-501.	5.2	9
77	Development and Validation of a Discriminatory Dissolution Method for Rifaximin Products. Journal of Pharmaceutical Sciences, 2019, 108, 2112-2118.	3.3	9
78	Development of stable amorphous solid dispersion and quantification of crystalline fraction of lopinavir by spectroscopic-chemometric methods. International Journal of Pharmaceutics, 2021, 602, 120657.	5.2	9
79	Perspectives of Quality by Design Approach in Nanomedicines Development. Current Nanomedicine, 2017, 7, .	0.6	9
80	Development of Abuse-Deterrent Formulations Using Sucrose Acetate Isobutyrate. AAPS PharmSciTech, 2020, 21, 99.	3.3	8
81	Regulatory Considerations in Development of Amorphous Solid Dispersions. Advances in Delivery Science and Technology, 2014, , 545-563.	0.4	7
82	Tulsi oil as a potential penetration enhancer for celecoxib transdermal gel formulations. Pharmaceutical Development and Technology, 2014, 19, 21-30.	2.4	7
83	Comparison of Univariate and Multivariate Models of 13C SSNMR and XRPD Techniques for Quantification of Nimodipine Polymorphs. AAPS PharmSciTech, 2015, 16, 1368-1376.	3.3	6
84	Nanoparticles for improvement in oral bioavailability. , 2019, , 371-410.		6
85	Studying effect of glyceryl palmitostearate amount, manufacturing method and stability on polymorphic transformation and dissolution of rifaximin tablets. International Journal of Pharmaceutics, 2020, 589, 119785.	5.2	6
86	Effects of Diluents on Physical and Chemical Stability of Phenytoin and Phenytoin Sodium. AAPS PharmSciTech, 2020, 21, 104.	3.3	6
87	Central Composite Designs and Their Applications in Pharmaceutical Product Development. , 2021, , 63-76.		6
88	Preparation and characterization of dicarboxylic acids salt of aripiprazole with enhanced physicochemical properties. Pharmaceutical Development and Technology, 2021, 26, 455-463.	2.4	6
89	Performance of Opportunistic Beam Selection for OWC System Under Foggy Channel with Pointing Error. IEEE Communications Letters, 2020, 24, 2029-2033.	4.1	6
90	In-use stability assessment of FDA approved metformin immediate release and extended release products for N-Nitrosodimethylamine and dissolution quality attributes. International Journal of Pharmaceutics, 2022, 623, 121923.	5.2	6

#	Article	IF	CITATIONS
91	Application of chemometric methods to differential scanning calorimeter (DSC) to estimate nimodipine polymorphs from cosolvent system. Drug Development and Industrial Pharmacy, 2015, 41, 995-999.	2.0	5
92	Nanotechnology to Combat Multidrug Resistance in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 245-272.	0.1	5
93	Univariate and Multivariate Models for Determination of Prasugrel Base in the Formulation of Prasugrel Hydrochloride Using XRPD Method. Journal of Pharmaceutical Sciences, 2019, 108, 3575-3581.	3.3	5
94	Application of salt engineering to reduce/mask bitter taste of clindamycin. Drug Development and Industrial Pharmacy, 2019, 45, 1871-1878.	2.0	5
95	Salt Engineering of Aripiprazole with Polycarboxylic Acids to Improve Physicochemical Properties. AAPS PharmSciTech, 2021, 22, 31.	3.3	5
96	Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection. Nanomedicine, 2022, 17, 959-978.	3.3	5
97	Development and Evaluation of a pH-Dependent Sustained Release Tablet for Irritable Bowel Syndrome. Drug Development and Industrial Pharmacy, 2009, 35, 57-64.	2.0	4
98	Development and validation of an ultraâ€highâ€performance liquid chromatography–tandem mass spectrometry method to determine the bioavailability of warfarin and its major metabolite 7â€hydroxy warfarin in rats dosed with oral formulations containing different polymorphic forms. Biomedical Chromatography, 2019, 33, e4685.	1.7	4
99	Development of a Multivariate Predictive Dissolution Model for Tablets Coated with Cellulose Ester Blends. Pharmaceuticals, 2020, 13, 311.	3.8	4
100	In-Situ Implant Formulation of Laurate and Myristate Prodrugs of Dolutegravir for Ultra-Long Delivery. Journal of Pharmaceutical Sciences, 2022, 111, 2312-2321.	3.3	4
101	Chemometric Evaluation of Brompheniramine–Tannate Complexes. Journal of Pharmaceutical Sciences, 2012, 101, 1450-1461.	3.3	3
102	Resistance to Targeted ABC Transporters in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , .	0.1	3
103	A headspace-gas chromatography method for isopropanol determination in warfarin sodium products as a measure of drug crystallinity. Acta Pharmaceutica, 2018, 68, 31-46.	2.0	3
104	Nanotechnology-based drug products. , 2018, , 619-655.		3
105	Coating characterization by hyperspectroscopy and predictive dissolution models of tablets coated with blends of cellulose acetate and cellulose acetate phthalate. AAPS PharmSciTech, 2021, 22, 122.	3.3	3
106	Effect of Transdermally Delivered Aspirin on Blood Coagulation Parameters. American Journal of Biomedical Sciences, 0, , 129-141.	0.2	3
107	Preparation and Characterization of Stable Amorphous Glassy Solution of BCS II and IV Drugs. AAPS PharmSciTech, 2022, 23, 35.	3.3	3
108	Nanomedicine Based Drug Targeting in Alzheimer's Disease: High Impact of Small Carter. , 2014, , 716-739.		2

#	Article	IF	CITATIONS
109	Sample Size for Tablet Compression and Capsule Filling Events During Process Validation. Journal of Pharmaceutical Sciences, 2017, 106, 3533-3538.	3.3	2
110	Is the demonstration of bioequivalence for clavulanic acid required in amoxicillin–clavulanic acid orally administered immediate-release products?. Journal of Pharmacy and Pharmacology, 2018, 70, 883-892.	2.4	2
111	Integrating QbD Tools for Flexible Scale-Up Batch Size Selection for Solid Dosage Forms. Journal of Pharmaceutical Sciences, 2020, 109, 1223-1230.	3.3	2
112	Evaluation of commercially available meth-deterrent pseudoephedrine hydrochloride products. International Journal of Pharmaceutics, 2020, 575, 118909.	5.2	2
113	Therapeutic Application of Microsponges-based Drug Delivery Systems. Current Pharmaceutical Design, 2022, 28, 595-608.	1.9	2
114	Using Metabolite Data to Develop Patient Centric Specification for Amide Impurity in Vildagliptin Tablets. Scientia Pharmaceutica, 2022, 90, 1.	2.0	2
115	Potential Application of USP Paddle and Basket Dissolution Methods in Discriminating for Portioned Moist Snuff and Snus Smokeless Tobacco Products. AAPS PharmSciTech, 2021, 22, 51.	3.3	1
116	Prospective Corollary of Ophthalmic Nanomedicine. , 2013, , 317-336.		1
117	Development and Validation of a Discriminatory Dissolution Method for Portioned Moist Snuff and Snus. Journal of Pharmaceutical Sciences, 2021, , .	3.3	1
118	Thermal Influence on Printlet Quality in the Selective Laser Sintering of Pharmaceutical Formulations. , 2020, , .		1
119	Frontiers in Anti-Cancer Drug Discovery. , 2014, , .		О